CURANEX PHARMACEUTICALS INC
CURXNASDAQ🏆 #4917 by market capUS Equity
$4.86▼ $0.34 (−6.63%)
Market closed · at closeTrack CURX
Get earnings, price moves & breaking news on Telegram
24h▼ 6.6%
7d▼ 6.6%
14d▼ 6.6%
30d▲ 5.8%
ytd▼ 27.1%
1y▼ 65.3%
🏦Market Cap
$8M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $4.86 – $4.86
- 52-Week Range
- $3.58 – $16.94
- Volume (shares)
- 114
- Avg Volume (shares)
- —
- Shares Outstanding
- 1.6M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-6.75
- Dividend Yield
- —
- Dilution (1yr)
- +2.1%
CURANEX PHARMACEUTICALS INC
CURXFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$4M▲ +1061.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$10M▲ +1787.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.4M▲ +2.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5M▲ +$4M YoY
StockOtter · stockotter.spaceAbout CURANEX PHARMACEUTICALS INC
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.